Paxman neuropathy device advances to FDA substantive review
PAX•Paxman’s De Novo application for its cryocompression device to prevent chemotherapy-induced peripheral neuropathy advanced to FDA substantive review after completing acceptance review. The 150-review-day target period began October 26, 2026, with 134 review days remaining.
1. FDA review advances
Paxman’s De Novo application for its cryocompression device to prevent chemotherapy-induced peripheral neuropathy advanced to FDA substantive review after completing acceptance review. The FDA will assess clinical, technical and supporting evidence.
2. Review timeline
The 150-review-day target period began October 26, 2026, with 134 review days remaining. Requests for additional information can pause the review clock while responses are prepared.
